$500 Million in mRNA Funding Cancelled: HHS Shifts Strategy for COVID and Flu Vaccines

What the announcement actually said—and what it didn’t.

Yesterday, the U.S. Department of Health and Human Services (HHS) announced a major shift in its vaccine development strategy, specifically related to mRNA technology for respiratory viruses like COVID-19 and influenza.

The HHS will wind down mRNA vaccine development efforts under its BARDA (Biomedical Advanced Research and Development Authority) division. This includes the termination of 22 federally funded mRNA-related projects, affecting nearly $500 million in contracts and solicitations.

Key changes include:

• Cancelled contracts with Moderna/UTMB for an mRNA-based H5N1 (avian flu) vaccine.

• Terminated research with Emory University, Tiba Biotech, and others.

• De-scoping of existing mRNA work with companies like Luminary Labs and Seqirus.

• Cancellation of pre-award solicitations from major players like Pfizer, Sanofi Pasteur, CSL Seqirus, Gritstone, and more.

• Wind-down of collaborations with the Department of Defense on nucleic acid-based vaccine programs.

A few late-stage projects (such as those with Arcturus and Amplitude) will be allowed to finish, but no new mRNA-based vaccine projects targeting respiratory viruses will be initiated under BARDA going forward.

Why the Change?

According to the statement from Secretary Kennedy:

"BARDA is terminating 22 mRNA vaccine development investments because the data show these vaccines fail to protect effectively against upper respiratory infections like COVID and flu. We're shifting that funding toward safer, broader vaccine platforms that remain effective even as viruses mutate."

In short: the decision was made after ,what the HHS states, is a comprehensive internal review of BARDA’s emergency-era investments. The goal? To refocus funding on technologies that show more promise in providing long-term protection, especially as respiratory viruses mutate rapidly.

---

What This Doesn’t Mean

In the hours since the announcement, headlines and hot takes have flooded social media, with some expressing fear or outrage that this signals the end of mRNA technology entirely.

Let’s pause there.

Nowhere in this announcement does HHS say it is abandoning all mRNA research. In fact, the statement explicitly notes that “other uses of mRNA technology within the department are not impacted.”

So while this is a clear pivot away from mRNA for respiratory viruses under BARDA, it does not mean that mRNA development is being halted in areas like:

• Cancer vaccines

• Autoimmune disease research

• Rare genetic therapies

These areas remain active and, from what I’ve seen, are still receiving substantial investment and attention.

---

What Might Come Next?

HHS stated that BARDA’s future priorities will focus on:

• Whole-virus platforms

• Live-attenuated and protein subunit vaccines

• Technologies with more consistent durability and safety profiles

• Transparency in both clinical and manufacturing data

This pivot makes some sense—especially considering the challenges in keeping up with fast-mutating viruses like COVID-19 and flu. While mRNA technology had early promise and was scaled rapidly during the pandemic, it's fair for federal agencies to re-evaluate long-term effectiveness, especially in terms of durability, transmission reduction, manufacturing transparency and most importantly, safety.

---

Final Thoughts

The news cycle moves fast. Reactions move faster.

But this announcement deserves a measured, thoughtful response. This isn’t about shutting down science—it’s about redirecting resources toward more promising and proven technologies, particularly for the ever-evolving category of respiratory viruses.

The takeaway? mRNA isn’t being abandoned—it’s being repositioned.

Let’s stay curious. Let’s stay critical. And let’s not jump to conclusions before we’ve read the actual policy shift.

—
Dr. Joel “Gator” Warsh
Integrative Pediatrician | Author of Between a Shot and Hard Place | @DrJoelGator